A Novel Pulsatile Release Film Coated Tablet of Zaltoprofen Loaded SNEDDS
-
Published:2021-08-06
Issue:
Volume:
Page:4287-4290
-
ISSN:0974-360X
-
Container-title:Research Journal of Pharmacy and Technology
-
language:en
-
Short-container-title:RJPT
Author:
Kalamkar Rajan1, Wadher Shailesh1, Jain Ashish2
Affiliation:
1. School of Pharmacy, SRTM University, Nanded. 2. Shri D. D. Vispute College of Pharmacy and Research Center, Panvel.
Abstract
The aim of the present study was to formulate pulsatile release film coated tablet of zaltoprofen for the treatment of rheumatoid arthritis. Initially solubility of zaltoprofen was enhanced by formulating self emulsifying fast disintegrating tablet of zaltoprofen. Core fast disintegrating tablet of zaltoprofen was coated with ethyl cellulose and eudragit L100 in various proportions as coating polymer. Ethanol was used as coating solvent and dibutyl phthalate as plasticizer. Film coated tablet with different coating levels were formulated and were evaluated for parameters like lag time, rupture time, in vitro dissolution etc. Amongst the nine different formulations P-4 formulation containing 3:1 ratio of ethyl cellulose and eudragit L100 with 5% coating level gives desired lag time with best drug dissolution profile. Formulated film coated tablet of zaltoprofen can be useful for chronotherapeutic treatment of rheumatoid arthritis.
Publisher
A and V Publications
Subject
Pharmacology (medical),Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference18 articles.
1. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative, Arthritis Rheum. 2010; 62 (9): 2569–2581. 2. Grassi W, De Angelis R, Lamanna G, Cervini C. The clinical features of rheumatoid arthritis, Eur. J. Radiol. Eur J Radiol. 1998: 18-24. 3. Crielaard BJ, Lammers T, Schiffelers RM, Storm G. Storm, Drug targeting systems for inflammatory disease: one for all, all for one. J Control Release. 2012; 161(2): 225-234. 4. Gibofsky A. Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis, Am. J. Manage. Care 2012; 18 (13): 295–302. 5. Croff ord LJ: Use of NSAIDs in treating patients with arthritis. Arthritis Research & Therapy 2013, 15(3): 2.
|
|